美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

PhaseRx, Inc.

0.2806

0.0000

成交量：- -

成交額：- -

市值：328.02萬

市盈率：-0.23

高：0.2806

開：0.2806

低：0.2806

收：0.2806

52周最高：1.95

52周最低：0.2228

股本：1,169.00萬

流通股本：370.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-1.2400

淨資產收益率：--

總資產收益率：--

市淨率：-10.90

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

PhaseRx, Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.phaserx.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

PhaseRx, Inc.作為一個特拉華州的公司成立於2006年3月9日。公司是一家臨床生物製藥公司，主要開發利用細胞內的酶替代療法，或稱為I-ERT，來治療肝臟酶的遺傳缺陷的產品組合，並期望在2018年能提取到臨床安全性和有效性的數據。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PZRX/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PZRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PZRX\",,,,,undefined,":{"symbol":"PZRX","market":"US","secType":"STK","nameCN":"PhaseRx, Inc.","latestPrice":0.2806,"timestamp":1517605200000,"preClose":0.2806,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":3700000,"shares":11690000,"eps":-1.24,"marketStatus":"已收盤","change":0,"latestTime":"02-02 16:00:00 EST","open":0.2806,"high":0.2806,"low":0.2806,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.24,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1781078400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1463544000000,"exchange":"NASDAQ","adjPreClose":0.2806,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PZRX\",,,,,undefined,":{"symbol":"PZRX","floatShares":3700000,"roa":"--","roe":"--","lyrEps":0,"shares":11690000,"dividePrice":0,"high":0.2806,"amplitude":0,"preClose":0.2806,"low":0.2806,"week52Low":0.2228,"pbRate":"-10.90","week52High":1.95,"institutionHeld":0,"latestPrice":0.2806,"eps":-1.24,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.24,"open":0.2806,"prevYearClose":0.2806},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PZRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-11-09","symbol":"PZRX","fiscalQuarterEnding":"2017/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1510203600000,"reportTimeType":"","actualEps":-0.23},{"market":"US","date":"2017-08-10","symbol":"PZRX","fiscalQuarterEnding":"2017/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1502337600000,"reportTimeType":"","actualEps":-0.3},{"market":"US","date":"2017-05-12","symbol":"PZRX","fiscalQuarterEnding":"2017/03","expectedEps":-0.06,"name":null,"time":"","type":"earning","dateTimestamp":1494561600000,"reportTimeType":"","actualEps":-0.35},{"market":"US","date":"2017-03-27","symbol":"PZRX","fiscalQuarterEnding":"2016/12","expectedEps":-0.22,"name":null,"time":"","type":"earning","dateTimestamp":1490587200000,"reportTimeType":"","actualEps":-0.3},{"market":"US","date":"2016-11-07","symbol":"PZRX","fiscalQuarterEnding":"2016/09","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1478494800000,"reportTimeType":"","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PZRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PZRX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.phaserx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.0916},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.2338},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"PhaseRx, Inc.作為一個特拉華州的公司成立於2006年3月9日。公司是一家臨床生物製藥公司，主要開發利用細胞內的酶替代療法，或稱為I-ERT，來治療肝臟酶的遺傳缺陷的產品組合，並期望在2018年能提取到臨床安全性和有效性的數據。","exchange":"NASDAQ","name":"PhaseRx, Inc.","nameEN":"PhaseRx"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PZRX\",market:\"US\",,,undefined,":null}}